DURECT Corp
DRRX1.910USD
0.000
Close 11/04, 16:00（ET）Quotes delayed by 15 min
59.29MMarket Cap
LossP/E TTM
More Details of DURECT Corp Company
DURECT Corporation is a late-stage biopharmaceutical company. The Company is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcoholic hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Therapy designation, and metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. Its commercial pharmaceutical product includes POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology. It has also completed Alcohol-Associated Hepatitis (AHFIRM) Phase 2b study.
DURECT Corp Info
Ticker SymbolDRRX
Company nameDURECT Corp
IPO dateSep 28, 2000
CEOMr. James E. Brown
Number of employees21
Security typeOrdinary Share
Fiscal year-endSep 28
Address10240 Bubb Road
CityCUPERTINO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code95014
Phone14087771417
Websitehttps://www.durect.com/
Ticker SymbolDRRX
IPO dateSep 28, 2000
CEOMr. James E. Brown
Company Executives of DURECT Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Ashley Robinson
Mr. Ashley Robinson
Investor Relations Officer
Investor Relations Officer
--
--
Mr. Timothy M. Papp
Mr. Timothy M. Papp
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. James E. Brown
Mr. James E. Brown
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Norman L. Sussman, M.D.
Dr. Norman L. Sussman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Ashley Robinson
Mr. Ashley Robinson
Investor Relations Officer
Investor Relations Officer
--
--
Mr. Timothy M. Papp
Mr. Timothy M. Papp
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. James E. Brown
Mr. James E. Brown
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Norman L. Sussman, M.D.
Dr. Norman L. Sussman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
No Data
By RegionUSD
Name
Revenue
Proportion
Europe
324.00K
72.48%
Other
63.00K
14.09%
United States
60.00K
13.42%
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Sep 14
Updated: Sun, Sep 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Asen (Scott R.)
10.31%
Richmond Brothers, Inc.
4.68%
Ingalls & Snyder LLC (Asset Management)
4.35%
The Vanguard Group, Inc.
4.08%
Dalton Investments, Inc.
2.40%
Other
74.18%
Shareholders
Shareholders
Proportion
Asen (Scott R.)
10.31%
Richmond Brothers, Inc.
4.68%
Ingalls & Snyder LLC (Asset Management)
4.35%
The Vanguard Group, Inc.
4.08%
Dalton Investments, Inc.
2.40%
Other
74.18%
Shareholder Types
Shareholders
Proportion
Investment Advisor
12.51%
Individual Investor
11.00%
Investment Advisor/Hedge Fund
9.79%
Hedge Fund
0.60%
Research Firm
0.27%
Venture Capital
0.04%
Other
65.80%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
108
10.77M
34.70%
-3.79M
2025Q1
115
10.47M
33.77%
-4.69M
2024Q4
121
10.25M
33.03%
-6.31M
2024Q3
136
10.05M
32.37%
-5.85M
2024Q2
154
9.42M
30.55%
-4.23M
2024Q1
183
8.84M
28.67%
-5.03M
2023Q4
192
7.39M
25.17%
-5.35M
2023Q3
219
10.25M
37.42%
-1.75M
2023Q2
226
9.55M
39.01%
-2.60M
2023Q1
233
10.65M
43.65%
-399.75K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Asen (Scott R.)
--
0%
+122.53K
-100.00%
Richmond Brothers, Inc.
--
0%
+107.33K
-100.00%
Ingalls & Snyder LLC (Asset Management)
--
0%
+14.64K
-100.00%
The Vanguard Group, Inc.
--
0%
--
--
Dalton Investments, Inc.
--
0%
+232.69K
-100.00%
Gagnon Securities LLC
--
0%
--
--
Geode Capital Management, L.L.C.
--
0%
-3.06K
-100.00%
Beirne Wealth Consulting Services, LLC
--
0%
+17.80K
-100.00%
Montchanin Asset Management, LLC
--
0%
+6.09K
-100.00%
BlackRock Institutional Trust Company, N.A.
--
0%
--
--
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 28, 2022
Merger
10→1
Nov 28, 2022
Merger
10→1
Nov 28, 2022
Merger
10→1
Nov 28, 2022
Merger
10→1
Date
Type
Ratio
Nov 28, 2022
Merger
10→1
Nov 28, 2022
Merger
10→1
Nov 28, 2022
Merger
10→1
Nov 28, 2022
Merger
10→1
